Promoters of accretion pharmaceuticals have confirmed that no shares were encumbered directly or indirectly during the financial year ended March 31, 2026. The declaration was submitted to the National Stock Exchange of India Limited on April 7, 2026, on behalf of all promoters and the promoter group, including persons acting in concert with them.

The disclosure was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, read with the SEBI (Substantial Acquisition of Shares and Takeovers) (Second Amendment) Regulations, 2019. This regulation requires promoters to annually disclose any encumbrance of shares held by them or the promoter group.

The declaration was signed by Harshad Nanubhai Rathod, Vivek Ashokkumar Patel, Hardik Mukundbhai Prajapati, and Mayur Popatlal Sojitra. Each promoter confirmed that they had not pledged or created any charge on their shareholdings during the specified period.

The letters were addressed to the Corporate Relations Department of the National Stock Exchange of India Limited. Copies of the disclosure were also marked to the Audit Committee of Accretion Pharmaceuticals Limited.

Key Disclosures

Accretion Pharmaceuticals Limited has announced its audited financial results for the year ended March 31, 2026. The company reported a robust financial performance with total income from operations reaching ₹89.63 crore, a significant increase of 56.21% compared to ₹57.38 crore in the previous year. This growth was primarily driven by volume expansion, an improved product mix, and better capacity utilization following the IPO. Profit after tax (PAT) for the year rose by 42.30% year-on-year to ₹9.67 crore, up from ₹6.79 crore in FY25.

Key Financial Highlights

The company's operational efficiency improved alongside revenue growth. EBITDA for the year stood at ₹14.95 crore, marking a 25.85% increase from the previous year's ₹11.88 crore. However, the EBITDA margin contracted to 16.68% in FY26 from 20.71% in FY25, attributed to higher input costs, manpower expenses for regulatory activities, and one-time IPO-related costs. The board has also recommended a dividend, though specific details were not disclosed in the immediate release.

H2 FY26 Performance

In the second half of the fiscal year, the company maintained its growth momentum. Net revenue for H2 FY26 stood at ₹45.89 crore, an increase of 18.24% from ₹38.81 crore in H2 FY25. PAT for the half-year grew by 13.55% to ₹4.92 crore. Management noted that growth was supported by new customer additions and ongoing product registrations across multiple geographies, with exports contributing 7.98% to H2 revenue.

Strategic Outlook

Management attributed the strong performance to healthy demand in export markets, particularly in Africa, Latin America, and Southeast Asia. The company continues to focus on scaling its Contract Development and Manufacturing Organization (CDMO) capabilities and transitioning towards higher-margin direct exports. With over 100 products under registration, Accretion Pharmaceuticals aims to deepen its international footprint and improve profitability through operating leverage in the coming year.